M. Van Schilfgaarde et al., Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity, MICROB PATH, 26(5), 1999, pp. 249-262
Nonencapsulated Haemophilus influenzae frequently persists in the lungs of
chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) patie
nts for prolonged periods of time. The bacteria are not eradicated by antib
iotic treatment of the patients or by specific antibodies that are found in
the sputum and sera of these patients. We investigated whether H. influenz
ae, when localized in lung epithelial cell layers, is shielded from antibio
tics and from antibody-mediated bactericidal activity of specific antibodie
s. An in vifro model system consisting of lung epithelial NCI-H292 cells on
permeable supports was developed to allow long term association of H. infl
uenzae with the cells. Microscopic examination showed increasing numbers of
H. influenzae bacteria between the epithelial cells up to 24 h of incubati
on. Coinciding with the microscopic observations the maximum number of cell
-associated bacteria surviving gentamicin treatment of the cell layers was
obtained after 24 h of incubation. All H. influenzae strains, and one Haemo
philus parainfluenzae strain tested penetrated into the cell layer as deter
mined by gentamicin killing. Cell-associated bacteria were shielded from th
e bactericidal activity of several antibiotics and from antibody-mediated b
actericidal activity. After prolonged incubation in the cell system in the
presence of a specific bactericidal antibody against major outer membrane p
rotein (MOMP) P2, antigenic variation occurred due to a point mutation in t
he MOMP P2 gene, similar to point mutations observed in vivo. We conclude t
hat penetration of H. influenzae between lung epithelial cells results in s
hielding the bacteria from killing by antibody dependent defense mechanisms
and by antibiotics. Therefore, penetration of H. influenzae between epithe
lial cells may contribute to the persistence of this microorganism in COPD
and CF patients. (C) 1999 Academic Press.